Chongqing PharscinPharmaceutical Co., Ltd. (abbreviated as "Pharscin Pharma") is acomprehensive pharmaceutical company with the functions of R&D,manufacturing and sales. The company focuses on both Chinese and Western medicines. On October 20, 2017, Pharscin Pharma launched its initial public offering of A shares on Shenzhen Stock Exchange.(Stock code 002907)
The company has 3 wholly owned subsidiaries, namely Chongqing Pharscin Medicine Co., Ltd., Chongqing Pharscin Pharmacy Retail Chain Co., Ltd. and Chongqing Pharscin Biotech Co., Ltd.
Guided by the technology-led and innovation-driven principle, Pharscin Pharma stays committed to manufacturing high quality products with special, sophisticated, unique and novel features. At present, we have 68 drug varieties, including Chinese patent medicine, APIs and finished pharmaceutical products. Among them 49 drugs are in the catalog of National Medical Insurance, 46 drugs have domestic patents and one has international patent.
Pharscin Pharma attaches great importance to scientific and technological innovation and has built a strong innovative platform for the transformation of scientific and technological achievements. We have successfully applied the key technologies such as extraction of thermosensitive active ingredients of traditional Chinese medicine, automatic transmission of powders and production control of soft capsules into manufacturing. The company is now in the process of building an automated information management system, purposely realizing the informative,internet-based, digital and intelligent management of production through the automated module control in every link of production.
Pharscin Pharma has built 11 domestically leading production lines for multiple dosage forms, including tablets, powders, granules, hard and soft capsules, powder for injection,freeze-dried powder for injection, small-volume injection, API syntheses and botanical drug extraction, etc.Our manufactured products have a 100% passing rate inthe finished products inspection, sampling inspection of the NMPA(former CFDA),national evaluation sampling inspection and market sampling inspection. We have won the honorary titles of the "Excellent Quality Management Team in thePharmaceutical Industry in China", the "National Excellent QualityManagement Team" and the "Safe and Reliable Medicines" published by the Ministry of Health. We enjoy a high reputation among consumers and medical workers.
Pharscin Pharma stays committed to academic promotion and has built a professional marketing team of more than 500 medical representatives to deliver the advanced, accurate and up-to-date information and services to medical workers.Our marketing network covers 31 provinces, cities andautonomous regions and is establishing its presence in overseas markets.
Since establishment of Phrasin Phama, we have always placed people first and respected talents. The company now has more than1000 staff, with more than 11% of our staff as senior professionals. This talent pool has put the long-term growth of the company on a firmer footing.
Pharscin Pharma takes“manufacturing quality medicine, safe-guarding for health” as its mission. The company stresses on R&D and academic promotion. Through IPO, we have raised funding to build a new cGMP compliant manufacturing facility for our company’s long-term commitment to provide high-quality and reliable specialty drugs for patients at home and abroad.